Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Janssen
INDICATIONS [/za_1193.html#1] [/za_1193.html#1] [/za_1193.html#1] CONTRA-INDICATIONS [/za_1193.html#1] [/za_1193.html#1] DOSAGE [/za_1193.html#1] [/za_1193.html#1] SIDE-EFFECTS [/za_1193.html#1] [/za_1193.html#1] [/za_1193.html#1] PREGNANCY [/za_1193.html#1] [/za_1193.html#1] OVERDOSE [/za_1193.html#1] IDENTIFICATION [/za_1193.html#1] [/za_1193.html#1] PATIENT INFORMATION GYNO-DAKTARIN® COMBIPAK SCHEDULING STATUS: Schedule 1 PROPRIETARY NAME (and dosage form): GYNO-DAKTARIN ® COMBIPAK COMPOSITION a) Each vaginal capsule contains 400 mg of the active substance MICONAZOLE nitrate with sodium ethylparaben 0,073% m/m and sodium propylparaben 0,036% m/m as preservatives. b) Each 5 g of cream contains 100 mg of the active substance, miconazole nitrate and 0,2% m/m of benzoic acid as preservative. PHARMACOLOGICAL CLASSIFICATION A.18.6 Medicines acting on genito-urinary system. Vaginal preparations. PHARMACOLOGICAL ACTION PHARMACODYNAMICS Miconazole combines a potent antifungal activity against common dermatophytes and yeasts with an antibacterial activity against certain gram-positive bacilli and cocci. Miconazole inhibits the biosynthesis of ergosterol in fungi and changes the composition of other lipid components in the membrane, resulting in fungal cell necrosis. PHARMACOKINETICS After the capsule has been inserted into the vagina, the outer covering rapidly disintegrates and the active suspension is almost instantaneously released. Systemic absorption after intravaginal administration is limited. Unchanged miconazole could not be traced in blood plasma or urine. INDICATIONS For the relief of vaginal itching, burning and discharge associated with recurrent vaginal yeast infections. (Vaginal candidiasis). CONTRA-INDICATIONS Contra-indicated in individuals who have shown hypersensitiv Read the complete document